Altfest L J & Co. Inc. Makes New Investment in Bruker Corporation $BRKR

Altfest L J & Co. Inc. bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,520 shares of the medical research company’s stock, valued at approximately $439,000.

A number of other institutional investors have also recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its stake in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares during the period. Spire Wealth Management bought a new position in shares of Bruker during the 2nd quarter valued at approximately $32,000. Parallel Advisors LLC raised its holdings in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares during the period. Finally, True Wealth Design LLC raised its holdings in Bruker by 16,716.7% during the 2nd quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after buying an additional 1,003 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

BRKR stock opened at $48.11 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The business has a 50-day moving average price of $44.67 and a 200 day moving average price of $39.25. The company has a market capitalization of $7.31 billion, a P/E ratio of -300.69, a PEG ratio of 6.23 and a beta of 1.17. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period in the prior year, the business earned $0.60 EPS. The firm’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Buying and Selling

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director owned 35,212 shares in the company, valued at $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Bank of America boosted their target price on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Cowen reiterated a “hold” rating on shares of Bruker in a report on Tuesday, November 4th. Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company upped their price target on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $51.38.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.